ProCE Banner Activity

Recent Advances in Advanced Osteosarcoma and Nonadipocytic Soft Tissue Sarcoma With TKI Therapy

Clinical Thought
Here are my thoughts on the current and potential future roles of TKIs in advanced osteosarcoma and nonadipocytic soft tissue sarcoma.

Released: May 25, 2022

Expiration: May 24, 2023

No longer available for credit.

Share

Faculty

Robin L. Jones

Robin L. Jones, BSc, MBBS, MRCP, MD (Res)

Professor
Sarcoma Unit
Royal Marsden Hospital and Institute of Cancer Research
London, United Kingdom

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Bayer Healthcare Pharma

Faculty Disclosure

Primary Author

Robin L. Jones, BSc, MBBS, MRCP, MD (Res)

Professor
Sarcoma Unit
Royal Marsden Hospital and Institute of Cancer Research
London, United Kingdom

Robin L. Jones, BSc, MBBS, MRCP, MD(Res), has disclosed that he has received consulting fees from Adaptimmune, Astex, Athenex, Bayer, BI, Blueprint, Clinigen, Daichii Sankyo, Deciphera, Eisai, Epizyme, Immunedesign, Immunicum, Karma Oncology, Lilly, Merck, Mundipharma, PharmaMar, Spring Works, SynOx, and Tracon.